TREATMENT OF EXTREMELY PREMATURE NEWBORN INFANT WITH INO. CLINICAL CASE
Keywords:bronchopulmonary dysplasia, pulmonary hypertension, extremely premature infant, inhaled nitric oxide
Prolonged inhaled nitric oxide (iNO) from birth in preterm neonates with BPD improves endogenous surfactant function as well as lung growth, angiogenesis, and alveologenesis. As a result there is a reduction in the frequency of the “new” form of BPD in neonates under 28 weeks of gestation and birth weight under 1000 gr. Delivery of inhaled nitric oxide is a new method of prevention of chronic lung disease. According to a large number of randomized trials iNO in premature neonates reduces pulmonary morbidity and leads to a reduction of the mortality in this population of patients. This new therapy does not have serious side effects. We represent a clinical case of extremely premature newborn infant with BPD treated with iNO.
I. Ann R. Stark, M.D. Inhaled NO for preterm infants – Getting to Yes?, N Engl J Med 2006; 355:404-406
II. Clark PL, Ekekezie II, Kaftan HA, Castor CA, Truog WE. Safety and efficacy of nitric oxide in chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2002;86:F41-F45
III. Kang JL, Park W, Pack IS, et al. Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation. J Appl Physiol 2002;92:795-801
IV. Haynes RL, Baud O, Kinney HC, Volpe JJ, Folkerth DR. Oxidative and nitrative injury in periventricular leukomalacia: a review. Brain Pathol 2005;15:225-233
V. Laptook AR, O'Shea TM, Shankaran SS, Bhaskar B. Adverse neurodevelopmental outcomes among extremely low birth weight infants with a normal head ultrasound: prevalence and antecedents. Pediatrics 2005;115:673-680
VI. William ETruog. (2007) Inhaled nitric oxide for the prevention of bronchopulmonary dysplasia. Expert Opinion on Pharmacotherapy 8:10.1517/eop.2007.8.issue-10, 1505-1513
VII. Frances Lilian LanhellasGonçalves, Rebeca LopesFigueira, Ana Leda BertonciniSimões, Rodrigo MeloGallindo, AllanColeman, José LuisPeiró, LourençoSbragia. (2014) Effect of corticosteroids and lung ventilation in the VEGF and NO pathways in congenital diaphragmatic hernia in rats. Pediatric Surgery International 30, 1207-1215
VIII. Pierre R.Provost, EricBoucher, YvesTremblay. (2013) Glucocorticoid metabolism in the developing lung: Adrenal-like synthesis pathway. The Journal of Steroid Biochemistry and Molecular Biology
IX. A Peliowski; Canadian Paediatric Society, Fetus and Newborn Committee Paediatr Child Health 2012;17(2):95-7 Inhaled nitric oxide use in newborns
X. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term.,Cochrane Database Syst, Rev 2006;(4):CD000399
XI. Konduri GG, Solimano A, Sokol GM, et al; Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics 2004;113:559-64.
XII. Konduri GG, Vohr B, Robertson C, et al; Neonatal Inhaled Nitric Oxide Study Group. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: Neurodevelopmental follow-up. J Pediatr 2007;150:235-40.
XIII. Van Meurs KP, Wright LL, Ehrenkranz RA, et al; Preemie Inhaled Nitric Oxide Study. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005;353:13-22.
XIV. Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants Cochrane Database Syst Rev 2010;(12):CD000509.
XV. Tanaka Y, Hayashi T, Kitajima H, Sumi K, Fujimura M. Inhaled nitric oxide therapy decreases the risk of cerebral palsy in preterm infants with persistent pulmonary hypertension of the newborn. Pediatrics 2007;119:1159-64.
XVI. Mestan KK, Marks JD, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med 2005;353:23-32.
XVII. Chock VY, Van Meurs KP, Hintz SR, et al; NICHD Neonatal Research Network. Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia. Am J Perinatol 2009;26:317-22.
XVIII. Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med. 2006;355(4):354 –364
XIX. Ballard PL, Gonzales LW, Godinez RI, et al. Surfactant composition and function in a primate model of infant chronic lung disease: effects of inhaled nitric oxide. Pediatr Res. 2006;59(1):157–162 Jan
XX. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336(9):597– 604
XXI. Clark RH, Kueser TJ, Walker MW, et al. Low dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med. 2000;342(7):469–474
XXII. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med. 2003;349(22): 2099 –2107
XXIII. Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006; 355(4):343–353
XXIV. Kinsella JP, Walsh WF, Bose CL, et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet. 1999; 354(9184):1061–1065
XXV. Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005;353(1):13–22
XXVI. Angus DC, Clermont G, Watson RS, Linde- Zwirble WT, Clark RH, Roberts MS. Costeffectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics. 2003;112(6 pt 1): 1351–1360
XXVII. Lorch SA, Cnaan A, Barnhart K. Costeffectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn. Pediatrics. 2004;114(2):417– 426
XXVIII. Victorian Infant Collaborative Study Group. Economic outcome for intensive care of infants of birth weight 500 –999 g born in Victoria in the post surfactant era. J Paediatr Child Health. 1997;33(3):202–20
XXIX. Hintz SR, Van Meurs KP, Perritt R, et al. Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized, controlled trial of inhaled nitric oxide. J Pediatr. 2007;151(1):16–22
XXX. Mestan KK, Marks JD, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med. 2005;353(1):23–32
XXXI. Finer N, Barrington K. Nitric oxide for respiratory failure in infants born at or near term (Cochrane Review). The Cochrane Library, Oxford: Update Software 2000; (2).
XXXII. Clark R H, Kueser T J, Walker M W, Southgate W M, Huckaby J L, Perez J A, et al. Low dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. The New England Journal of Medicine 2000; 342 (7): 469-474.
XXXIII. Subhedar N, Ryan S W, Shaw N J. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 77 (3): F185-190.
XXXIV. Subhedar N, Shaw N J. Changes in oxygenation and pulmonary haemodynamics in preterm infants treated with inhaled nitric oxide. Arch Dis Child Fetal Neonatal Ed 1997; 77 (3): F191-197.
XXXV. Mercier J C, et al. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. The Lancet 1999; 354 (9184): 1066-1071.
XXXVI. Rosenburg A. Inhaled nitric oxide in the premature infant with severe hypoxaemic respiratory failure: a time for caution. The Journal of Pediatrics 1997; 133 (6): 720-722.
XXXVII. Hess D. Adverse effects and toxicity of inhaled nitric oxide. Respiratory Care 1999; 44 (3): 315-330.
XXXVIII. Jones C. Inhaled nitric oxide: are the safety issues being addressed? Intensive and Critical Care Nursing 1998; 14: 271-275.
How to Cite
Copyright (c) 2022 International Education and Research Journal (IERJ)
This work is licensed under a Creative Commons Attribution 4.0 International License.